MGD024

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

Near Add Your Location

Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients

MDS Center of Excellence

All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Accepting patients

MDS Center of Excellence

Duke Cancer Center
Duke University Medical Center
Durham, NC
  • Not yet accepting

MDS Center of Excellence

University of Maryland Medical Center
Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, MD
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.